Trial Profile
A Phase II Trial of AZD0530 in Previously Treated Metastatic Pancreas Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Saracatinib (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 04 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jan 2013 Planned end date changed from 1 Jan 2100 to 1 Apr 2011 as reported by ClinicalTrials.gov record.